Supramolecular cancer nanotheranostics

2021 ◽  
Vol 50 (4) ◽  
pp. 2839-2891
Author(s):  
Jiong Zhou ◽  
Lang Rao ◽  
Guocan Yu ◽  
Timothy R. Cook ◽  
Xiaoyuan Chen ◽  
...  
Keyword(s):  
Early Stage ◽  
Personal Therapy ◽  
Theranostic Agents

Supramolecular cancer nanotheranostics have shown promising potentials in early-stage diagnosis and personal therapy. Herein, we summarize the progress of supramolecular cancer nanotheranostics and provide guidance for designing new targeted supramolecular theranostic agents.

scholarly journals Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Symmetry ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 974
Author(s):  
Md. Abu Rayhan ◽  
Md. Sakib Hossen ◽  
Mahruba Sultana Niloy ◽  
Mozammel Haque Bhuiyan ◽  
Sudip Paul ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Iron Oxide ◽  
Early Diagnosis ◽  
Anticancer Agents ◽  
Early Stage ◽  
Treatment Strategies ◽  
Fine Tuning ◽  
Diagnosis And Treatment ◽  
Theranostic Agents

Prostate cancer (PCa) is the most common malignancy in men and the leading cause of death for men all over the world. Early diagnosis is the key to start treatment at an early stage of PCa and to reduce the death toll. Generally, PCa expresses characteristic morphologic features and serum biomarkers; however, early diagnosis is challenging due to its heterogeneity and long-term indolent phase in the early stage. Following positive diagnosis, PCa patients receive conventional treatments including surgery, radiation therapy, androgen deprivation therapy, focal therapy, and chemotherapy to enhance survival time and alleviate PCa-related complications. However, these treatment strategies have both short and long-term side effects, notably impotence, urinary incontinence, erectile dysfunctions, and recurrence of cancer. These limitations warrant the quest for novel PCa theranostic agents with robust diagnostic and therapeutic potentials to lessen the burden of PCa-related suffering. Iron oxide nanoparticles (IONPs) have recently drawn attention for their symmetrical usage in the diagnosis and treatment of several cancer types. Here, we performed a systematic search in four popular online databases (PubMed, Google Scholar, Scopus, and Web of Science) for the articles regarding PCa and IONPs. Published literature confirmed that the surface modification of IONPs with biopolymers and diagnostic biomarkers improved the early diagnosis of PCa, even in the metastatic stage with reliable accuracy and sensitivity. Furthermore, fine-tuning of IONPs with biopolymers, nucleic acids, anticancer drugs, and bioactive compounds can improve the therapeutic efficacy of these anticancer agents against PCa. This review covers the symmetrical use of IONPs in the diagnosis and treatment of PCa, investigates their biocompatibility, and examines their potential as PCa theranostic agents.

Recent Advances in Superparamagnetic Iron Oxide Based Nanoprobes as Multifunctional Theranostic Agents for Breast Cancer Imaging and Therapy

2018 ◽  
Vol 25 (25) ◽  
pp. 3001-3016 ◽  
Author(s):  
Jianjun Zheng ◽  
Wenzhi Ren ◽  
Tianxiang Chen ◽  
Yinhua Jin ◽  
Aijing Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surface Modification ◽  
Iron Oxide ◽  
Radiation Dose ◽  
Early Stage ◽  
Superparamagnetic Iron Oxide ◽  
Breast Cancer Imaging ◽  
Diagnose Breast Cancer ◽  
Recent Advances ◽  
Theranostic Agents

Background: Breast cancer accounts for nearly one in three cancers, and it is the most common cancer diagnosed among women. The death rate of breast cancer is estimated to be 14%. Hence, accurate diagnosis in early stage and effective treatment in any stage are critical for the survival of breast cancer. Mammogram has been the most common technique administered to detect breast cancer. However, the radiation dose from mammogram is harmful to patients. Fortunately, magnetic resonance imaging (MRI) can diagnose breast cancer without any radiation dose, and enhanced MRI can make earlier and differential diagnosis. Therefore, as contrast materials, superparamagnetic iron oxide based nanoprobes (SPIONs) have generated a great deal of attention. Objective: This review covers recent advances in SPIONs as multifunctional theranostic agents. Methods: Besides synthesis and surface modification of SPIONs, passive and active targeted imaging is also discussed. Moreover, a serial of potential therapy for breast cancer is further described, such as photodynamic therapy, photothermal therapy, chemotherapy and magnetic hyperthermia therapy. Conclusion: Preparation and surface modification of SPIONs is critical for imaging diagnosis of breast cancer and further potential treatment.

An assessment of in-vitro and in-vivo evaluation methods for theranostic nanomaterials

2021 ◽  
Vol 27 ◽  
Author(s):  
Poonam Parashar ◽  
Neelu Singh ◽  
Alka Alka ◽  
Priyanka Maurya ◽  
Shubhini A. Saraf
Keyword(s):  
Surface Engineering ◽  
Early Stage ◽  
Evaluation Criteria ◽  
In Vivo Evaluation ◽  
Size Dependent ◽  
Entry Points ◽  
Theranostic Agents ◽  
Diagnostic Agent

: Nanoparticles (NPs) as nanocarriers have emerged as novel and promising theranostic agents. The term theranostics revealed the properties of NPs capable of diagnosing the disease at an early stage and/or treating the disease. Such NPs are usually developed employing a surface engineering approach. The theranostic agents comprise NPs loaded with a drug/diagnostic agent that delivers it precisely to the target site. Theranostics is a field with promising results in enhancing therapeutic efficacy facilitated through higher payload at the targeted tissue, reduced dose, and dose-dependent side effects. However, controversies in terms of toxicity and size-dependent properties have often surfaced for NPs. Thus, a stringent in-vitro and in-vivo evaluation is required to develop safe and non-toxic NPs as theranostic agents. The review also focuses on the various entry points of NPs in the human system and their outcomes, including toxicity. It elaborates the evaluation criteria to ensure the safe use of NPs for diagnostic and therapeutic purposes.

Alterations in the number of motoneurons containing immunoreactive calcitonin gene-related peptide(CGRP)& choline acetyltransferase(ChAT) in the cervical spinal cord of the wobbler mouse during the development of the motoneuron disease

1995 ◽  
Vol 53 ◽  
pp. 970-971
Author(s):  
L. Vacca-Galloway ◽  
Y.Q. Zhang ◽  
P. Bose ◽  
S.H. Zhang
Keyword(s):  
Spinal Cord ◽  
Early Stage ◽  
Cervical Spinal Cord ◽  
Wild Type Mouse ◽  
Reflex Response ◽  
Mouse Strains ◽  
Behavioral Tests ◽  
Wobbler Mouse ◽  
Stage 4 ◽  
Stage 1

The Wobbler mouse (wr) has been studied as a model for inherited human motoneuron diseases (MNDs). Using behavioral tests for forelimb power, walking, climbing, and the “clasp-like reflex” response, the progress of the MND can be categorized into early (Stage 1, age 21 days) and late (Stage 4, age 3 months) stages. Age-and sex-matched normal phenotype littermates (NFR/wr) were used as controls (Stage 0), as well as mice from two related wild-type mouse strains: NFR/N and a C57BI/6N. Using behavioral tests, we also detected pre-symptomatic Wobblers at postnatal ages 7 and 14 days. The mice were anesthetized and perfusion-fixed for immunocytochemical (ICC) of CGRP and ChAT in the spinal cord (C3 to C5).Using computerized morphomety (Vidas, Zeiss), the numbers of IR-CGRP labelled motoneurons were significantly lower in 14 day old Wobbler specimens compared with the controls (Fig. 1). The same trend was observed at 21 days (Stage 1) and 3 months (Stage 4). The IR-CGRP-containing motoneurons in the Wobbler specimens declined progressively with age.

Automated high-resolution microscopy: the approaches so far

1987 ◽  
Vol 45 ◽  
pp. 58-61
Author(s):  
W. O. Saxton
Keyword(s):  
High Resolution ◽  
Early Stage ◽  
Automatic Recording ◽  
Microprocessor Control ◽  
Alternative Systems ◽  
Electron Image ◽  
Complete Automation ◽  
Analysis System ◽  
High Resolution Microscopy

Recent commercial microscopes with internal microprocessor control of all major functions have already demonstrated some of the benefits anticipated from such systems, such as continuous magnification, rotation-free diffraction and magnification, automatic recording of mutually registered focal series, and fewer control knobs. Complete automation of the focusing, stigmating and alignment of a high resolution microscope, allowing focal series to be recorded at preselected focus values as well, is still imminent rather than accomplished, however; some kind of image pick-up and analysis system, fed with the electron image via a TV camera, is clearly essential for this, but several alternative systems and algorithms are still being explored. This paper reviews the options critically in turn, and stresses the need to consider alignment and focusing at an early stage, and not merely as an optional extension to a basic proposal.

Direct observation of Fe-Al-Zn ternary intermetallic compound and its transformation during the early stage of hot-dip galvanizing

1993 ◽  
Vol 51 ◽  
pp. 1116-1117
Author(s):  
C. S. Lin ◽  
W. A. Chiou ◽  
M. Meshii
Keyword(s):  
Intermetallic Compound ◽  
Reaction Rate ◽  
Diffusion Rate ◽  
Early Stage ◽  
Zinc Bath ◽  
Steel Sheets ◽  
Direct Observations ◽  
Solid Iron ◽  
Iron And Zinc ◽  
Ternary Intermetallic Compound

The galvannealed steel sheets have received ever increased attention because of their excellent post-painting corrosion resistance and good weldability. However, its powdering and flaking tendency during press forming processes strongly impairs its performance. In order to optimize the properties of galvanneal coatings, it is critical to control the reaction rate between solid iron and molten zinc.In commercial galvannealing line, aluminum is added to zinc bath to retard the diffusion rate between iron and zinc by the formation of a thin layer of Al intermetallic compound on the surface of steel at initial hot-dip galvanizing. However, the form of this compound and its transformation are still speculated. In this paper, we report the direct observations of this compound and its transformation.The specimens were prepared in a hot-dip simulator in which the steel was galvanized in the zinc bath containing 0.14 wt% of Al at a temperature of 480 °C for 5 seconds and was quenched by liquid nitrogen.

Anisotropy of interfacial defects in the initial stage of MOVPE GaAs growth On Si

1990 ◽  
Vol 48 (4) ◽  
pp. 592-593
Author(s):  
C. Vannuffel ◽  
C. Schiller ◽  
J. P. Chevalier
Keyword(s):  
Early Stage ◽  
Threading Dislocations ◽  
Mbe Growth ◽  
Detailed Mechanism ◽  
Si Substrates ◽  
Initial Stage ◽  
Interfacial Defects ◽  
Interfacial Dislocations ◽  
Step Growth ◽  
Essential Problem

Recently, interest has focused on the epitaxy of GaAs on Si as a promising material for electronic applications, potentially for integration of optoelectronic devices on silicon wafers. The essential problem concerns the 4% misfit between the two materials, and this must be accommodated by a network of interfacial dislocations with the lowest number of threading dislocations. It is thus important to understand the detailed mechanism of the formation of this network, in order to eventually reduce the dislocation density at the top of the layers.MOVPE growth is carried out on slightly misoriented, (3.5°) from (001) towards , Si substrates. Here we report on the effect of this misorientation on the interfacial defects, at a very early stage of growth. Only the first stage, of the well-known two step growth process, is thus considered. Previously, we showed that full substrate coverage occured for GaAs thicknesses of 5 nm in contrast to MBE growth, where substantially greater thicknesses are required.

Nanotheranostic agents for neurodegenerative diseases

2020 ◽  
Vol 4 (6) ◽  
pp. 645-675
Author(s):  
Parasuraman Padmanabhan ◽  
Mathangi Palanivel ◽  
Ajay Kumar ◽  
Domokos Máthé ◽  
George K. Radda ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Diseases ◽  
Cell Types ◽  
Specific Cell ◽  
Ageing Population ◽  
Target Tissue ◽  
Therapeutic Approaches ◽  
Surface Receptors ◽  
Theranostic Agents ◽  
Preclinical Animal Models

Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), affect the ageing population worldwide and while severely impairing the quality of life of millions, they also cause a massive economic burden to countries with progressively ageing populations. Parallel with the search for biomarkers for early detection and prediction, the pursuit for therapeutic approaches has become growingly intensive in recent years. Various prospective therapeutic approaches have been explored with an emphasis on early prevention and protection, including, but not limited to, gene therapy, stem cell therapy, immunotherapy and radiotherapy. Many pharmacological interventions have proved to be promising novel avenues, but successful applications are often hampered by the poor delivery of the therapeutics across the blood-brain-barrier (BBB). To overcome this challenge, nanoparticle (NP)-mediated drug delivery has been considered as a promising option, as NP-based drug delivery systems can be functionalized to target specific cell surface receptors and to achieve controlled and long-term release of therapeutics to the target tissue. The usefulness of NPs for loading and delivering of drugs has been extensively studied in the context of NDDs, and their biological efficacy has been demonstrated in numerous preclinical animal models. Efforts have also been made towards the development of NPs which can be used for targeting the BBB and various cell types in the brain. The main focus of this review is to briefly discuss the advantages of functionalized NPs as promising theranostic agents for the diagnosis and therapy of NDDs. We also summarize the results of diverse studies that specifically investigated the usage of different NPs for the treatment of NDDs, with a specific emphasis on AD and PD, and the associated pathophysiological changes. Finally, we offer perspectives on the existing challenges of using NPs as theranostic agents and possible futuristic approaches to improve them.

1596: Choices for Definitive Treatment of Early-Stage Prostate Cancer: Results from the Compare Registry

2006 ◽  
Vol 175 (4S) ◽  
pp. 514-514
Author(s):  
David G. McLeod ◽  
Oliver Sartor ◽  
Paul F. Schellhammer ◽  
Anthony V. D'Amico ◽  
Susan Halabi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Stage ◽  
Definitive Treatment

644: Cathepsin D is a Marker for Early Stage Renal Cell Cancer and Predicts the Presence of Distant Metastases

2005 ◽  
Vol 173 (4S) ◽  
pp. 175-175
Author(s):  
Axel S. Merseburger ◽  
Joerg Hennenlotter ◽  
Perikles Simon ◽  
Marcus Horstmann ◽  
Arnulf Stenzl ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cathepsin D ◽  
Early Stage ◽  
Cell Cancer ◽  
Distant Metastases
Sign in / Sign up

Export Citation Format

Share Document